Three pivotal trials, a phase II randomized, IFN-β-compared trial (CAMMS223) and two phase III randomized, IFN-β-compared trials (CARE-MS I and CARE-MS II), evaluated the efficacy and safety profile of alemtuzumab in relapsing MS [109,110,111]. The gene discussed is IFNB1; the disease is myeloid sarcoma.